What is MBIO's 12-month stock price target?

Mustang Bio Inc. (MBIO) carries a 12-month consensus base price target of $0.39 (-7.1% from $0.42), with a bull-case target of $1.52 and a bear-case floor of $0.3.

Stock Ratings / Health Care / MBIO / forecast

CMND (47) ERNA (33) EOCN (34) SXTP (38) ⌘ Pro Terminal →

Mustang Bio Inc. (MBIO) 12-Month Stock Forecast & Price Target Cone

Q: Is MBIO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates MBIO D- (Sell — SELL) with an RQD Confidence score of 41/100.

$0.42 +3.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.42

Mustang Bio Inc. (MBIO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Mustang Bio Inc. (NASDAQ: MBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.42 (+3.72% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MBIO ranks #451 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MBIO compare to CMND and ERNA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBIO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M) and ERNA (Ernexa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, MBIO leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MBIO?

▼

Per MBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680048), Mustang Bio Inc. generated $6.8M in revenue (-85.0% YoY), -$1.9M in net income, and -$5.3M in free cash flow against $17.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.42 (+0.48%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY MBIO SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.38+0% Next Q

Q2 (-2Q)

Grade E$0.38-5.3% Next Q

Q3 (-1Q)

Grade E$0.36+16.7% Next Q

Current

Grade D-$0.42-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MBIO currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.47) and Max Pain ($0.44) forces dealer call-delta covering toward $1.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your MBIO Position Size: $10,000

Shares at $0.42: 23809.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.30

$7,143

$-2,857 (-28.6%)

12M Consensus BaseTarget $0.39

$9,286

$-714 (-7.1%)

12M Bull Case BreakoutTarget $1.52

$36,190

+$26,190 (+261.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$0	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$1	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBIO)

✓Walkthrough of MBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.00%⚡ TESTING RESISTANCE

2026-11-03O $0.39H $0.42L $0.39C $0.42VOL 48.3K

RES: $0.42SUP: $0.34SMA50: $0.47SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBIO Butterfly Map → + Track MBIO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -85.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBIO)

Health Care Rank #451 of 1015 ⚔️ CMND vs MBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBIO vs. CMND, ERNA, EOCN, SXTP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mustang Bio Inc. (MBIO) ranks #451 by composite RQD confidence (41/100, grade D-) and #976 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, MBIO leads on earnings valuation at N/A trailing P/E, while MBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBIO at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MBIO ACTIVE Mustang Bio Inc.	D-	41/100	—	—	-35.0%	+3.72%	$3.0M	Benchmark Subject
CMND Clearmind Medicine Inc.	D	47/100	—	—	—	-1.27%	$3.2M	/cmnd-vs-mbio →
ERNA Ernexa Therapeutics Inc.	E	33/100	—	—	-35.0%	-1.01%	$3.2M	/erna-vs-mbio →
EOCN Eocene Ltd.	E	34/100	—	—	-35.0%	-7.54%	$3.2M	/eocn-vs-mbio →
SXTP 60 Degrees Pharmaceuticals Inc.	D-	38/100	—	22.3%	-35.0%	-3.65%	$3.3M	/sxtp-vs-mbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680048 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mustang Bio Inc. (MBIO) reported GAAP revenue of $6.8M (-85.0% vs. FY2024 revenue of $45.5M , and -95.1% cumulative change since FY2023) , GAAP net income of -$1.9M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+53.9% YoY). On the balance sheet, MBIO closed FY2025 with $17.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.8M	-$1.9M	-$5.3M	-$5.3M	$17.6M	—
FY2024 (FY)	2024-12-31	$45.5M	-$15.8M	-$11.4M	-$11.4M	$9.3M	—
FY2023 (FY)	2023-12-31	$137.9M	-$51.6M	-$49.5M	-$49.5M	—	—

3. MBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MBIO compare to CMND and ERNA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MBIO?

Where is MBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

MBIO last traded at $0.42 (+3.72% on volume of 34,155 shares), positioning the stock -10.64% below its 50-day simple moving average ($0.47) and -38.24% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.35 to $1.45, MBIO sits at the 6.4% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.47).

Direct Sub-Reports: MBIO RQD Cockpit MBIO 12M Forecast MBIO Earnings & Move MBIO Dividends & DRIP MBIO Insiders & 13F MBIO Whale Options MBIO Profit Sankey MBIO News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MBIO — Mustang Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mustang Bio Inc. (MBIO) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.42 (+3.72% 1D, market capitalization $3.0M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (12/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mustang Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The SEC financials report revenue of — across the FY 2023, FY 2024, and FY 2025 periods, so the company is not generating reported revenue in the provided data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mustang Bio Inc. (MBIO) reported $6.8M in annual revenue (up from $45.5M in FY2024, -85.0% YoY) and -$1.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($137.9M revenue, -$51.6M net income) through FY2025, MBIO scaled operating cash flow to -$5.3M and free cash flow to -$5.3M, backed by $17.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.35 – $1.45 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MBIO carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can MBIO sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $6.8M and free cash flow of -$5.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is MBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mustang Bio Inc. (MBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MBIO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 22h ago

Mustang Bio, Inc. Estimates – NASDAQ:MBIO

TradingView report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Fortress Biotech, Inc. (FBIO) Seasonal returns chart

Yahoo Finance UK report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Mustang Bio gets Nasdaq reprieve. Mustang Bio stock needs USD 1.00 bids

ad-hoc-news.de report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Unusual Volume Stocks & Volume Spikes Today

TradingKey report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 173d ago

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB

Read Full Source ↗

🟡 MARKET WIRE Streetwise Reports • 14d ago

MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection Toward Commercial Pilot

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNYnNOcHktYllnb3NWd004TWFDU0o1WC1scDZGcEUtYWFXbXhfblJ4MXZNSGFzU29MZURSSXZ3dVV3UFZyNnhPZTFHZkJEMGVaY3hPemhDV1RvVVFsOWkxZGxBdTU4cmtwbkk4cS1qU005OGQ2bmlIc3dnYWh

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MBIO Bull vs. Bear Conversation Board — What's Your Call at $0.42?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBIO 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.47 (+17.5%)

📌 Pinned Debate

Reported cash rose to $17.3M in FY 2025 while net loss narrowed to -$1.9M from -$51.6M in FY 2023.

The street is overcomplicating Mustang Bio Inc. (MBIO). Reported cash rose to $17.3M in FY 2025 while net loss narrowed to -$1.9M from -$51.6M in FY 2023.. With an RQD score of 41/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.43.

EarningsSniper 🐂 BULL

@ShortSeller_Dan Shorting a 12/20 institutional whale-flow stock at $0.40 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.30 (-25.0%)

Spot @ $0.40

With a 39 RQD score, ROIC of -35%, zero FCF yield, and a $0.39 price amid a Nasdaq bid-price reprieve, the balance sheet and flow profi

Careful chasing MBIO at $0.40. With a 39 RQD score, ROIC of -35%, zero FCF yield, and a $0.39 price amid a Nasdaq bid-price reprieve, the balance sheet and flow profile look vulnerable.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.30 on multiple compression.